Thoracic and cutaneous sarcoid-like reaction associated with anti-PD-1 therapy: longitudinal monitoring of PD-1 and PD-L1 expression after stopping treatment.

J Immunother Cancer 2018 06 13;6(1):52. Epub 2018 Jun 13.

Service de Pneumologie, Centre Hospitalier Universitaire, 4 rue Larrey, 49000, Angers, France.

Background: Immune checkpoint inhibitors (ICI) target T cell inhibitory pathways that are responsible for cancer tolerance by down-modulating immune functions. ICI have revolutionized patients care with lung cancer. Nevertheless, restoring endogenous antitumor T-cell responses can induce immune related adverse events, such as sarcoidosis.

Case Presentation: We report here the first case of a thoracic and cutaneous sarcoid-like reaction in a patient with a relapsing unresectable non-small cell lung cancer (NSCLC) treated with nivolumab, an anti-PD-1 mAb. The expression of PD-1 and its ligands, PD-L1 and PD-L2, was assessed by flow cytometry on peripheral blood mononuclear cells (PBMC) and compared to patients who had discontinued nivolumab therapy without having developed any immune related adverse events. PD-L1 expression was transiently increased on B cells, T cells and monocytes, whereas PD-L2 expression was not modulated. PD-1 was transiently undetectable when PD-L1 was maximal, before returning to basal level. Sarcoidosis spontaneously resolved, without corticotherapy.

Conclusion: This case sheds the light on a complex regulation of PD-L1 expression in vivo on PBMC after nivolumab arrest and triggers the question of monitoring the expression of immune checkpoint on immune cells during and after treatment with ICI.

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-018-0372-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001149PMC
June 2018
17 Reads

Publication Analysis

Top Keywords

pd-l1 expression
12
immune checkpoint
8
lung cancer
8
adverse events
8
sarcoid-like reaction
8
immune adverse
8
cutaneous sarcoid-like
8
thoracic cutaneous
8
immune
6
expression
6
pd-l1
5
treated nivolumab
4
cancer nsclc
4
cell lung
4
nivolumab anti-pd-1
4
nsclc treated
4
spontaneously resolved
4
ligands pd-l1
4
pd-l1 pd-l2
4
sarcoidosis spontaneously
4

References

(Supplied by CrossRef)

JE Reuss et al.
J Immunother Cancer 2016

KC Suozzi et al.
JAAD Case Rep 2016

FX Danlos et al.
Chest 2016

J Brahmer et al.
N Engl J Med 2015

S Cousin et al.
Ann Oncol 2016

J Cotliar et al.
JAAD Case Rep 2016

MR Birnbaum et al.
JAAD Case Rep 2017

NA Braun et al.
Am J Respir Crit Care Med 2014

A Garcia-Diaz et al.
Cell Rep 2017

P Sakthivel et al.
Curr Opin Hematol 2017

Similar Publications